BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9930386)

  • 41. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion.
    Collen MJ; Strong RM
    Dig Dis Sci; 1992 Jun; 37(6):897-903. PubMed ID: 1587194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications.
    Bechi P; Bacci S; Cianchi F; Amorosi A; Nesi G; Dei R; Romagnoli P
    Dig Dis Sci; 2001 Sep; 46(9):1952-9. PubMed ID: 11575448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.
    Hatlebakk JG; Berstad A
    Scand J Gastroenterol; 1996 Oct; 31(10):954-8. PubMed ID: 8898414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.
    Tomassetti P; Salomone T; Migliori M; Campana D; Corinaldesi R
    Drugs Aging; 2003; 20(14):1019-34. PubMed ID: 14651442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
    Komazawa Y; Adachi K; Mihara T; Ono M; Kawamura A; Fujishiro H; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Jun; 18(6):678-82. PubMed ID: 12753150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 59-year-old woman with gastroesophageal reflux disease and Barrett esophagus.
    Spechler SJ
    JAMA; 2003 Jan 22-29; 289(4):466-75. PubMed ID: 12533126
    [No Abstract]   [Full Text] [Related]  

  • 48. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
    Holtmann G; Cain C; Malfertheiner P
    Gastroenterology; 1999 Jul; 117(1):11-6. PubMed ID: 10381904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?
    Soga T; Matsuura M; Kodama Y; Fujita T; Sekimoto I; Nishimura K; Yoshida S; Kutsumi H; Fujimoto S
    J Gastroenterol; 1999 Aug; 34(4):435-40. PubMed ID: 10452673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice.
    Medhi B; Prakash A
    Scand J Gastroenterol; 2008 Aug; 43(8):1022-3; author reply 1024. PubMed ID: 19086171
    [No Abstract]   [Full Text] [Related]  

  • 54. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
    Graham DY
    Am J Med; 2001 Jan; 110(1A):58S-61S. PubMed ID: 11166000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Gastroesophageal reflux disease and Helicobacter pylori].
    Aruin II; Isakov VA
    Klin Med (Mosk); 2000; 78(10):62-8. PubMed ID: 11220906
    [No Abstract]   [Full Text] [Related]  

  • 58. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
    Hashimoto H; Kushikata T; Kudo M; Hirota K
    J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.